A phase I, randomised, double- blind and placebo- controlled trial designed to evaluate the safety, tolerability and pharmacokinetics of CT-P63 in healthy subjects
Latest Information Update: 11 Jan 2022
At a glance
- Drugs Regdanvimab and CT P63 antibody cocktail-Celltrion (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- 11 Jan 2022 New trial record
- 03 Jan 2022 Results published in a Celltrion Media Release.